Metal-Organic Framework-Based Nanomedicines for Cancer Therapy: A Proposed Delivery Framework for Executable Cuproptosis
Summary
Metal-organic frameworks (MOFs) can coordinate copper, catalytic sites and therapeutic cargo within one carrier, offering opportunities to control copper exposure and cellular susceptibility. Establishing their contribution to cuproptosis requires evidence connecting these design functions to copper delivery and the cell-death mechanism. This critical narrative review proposes "executable cuproptosis" as a delivery and evaluation framework for examining that connection.
Keywords
Metal-organic frameworks (MOFs) can coordinate copper, catalytic sites and therapeutic cargo within one carrier, offering opportunities to control copper exposure and cellular susceptibility. Establishing their contribution to cuproptosis requires evidence connecting these design functions to copper delivery and the cell-death mechanism. This critical narrative review proposes "executable cuproptosis" as a delivery and evaluation framework for examining that connection. We assess selected MOF platforms across mechanistic validation, mitochondrial access, tumor context and translational requirements, with comparisons to other copper-delivery approaches. The reviewed examples show that material design can influence copper release, retention and treatment responses, while evidence linking these effects to mitochondrial copper and cuproptosis-specific causality remains uneven. Copper accumulation, carrier colocalization, oxidative stress and tumor inhibition support different claims; their interpretation depends on the measurement and functional controls. Combination studies require quantitative assessment of interaction and separate validation of each claimed death pathway or immune effect. Pharmacokinetic, biodistribution and long-term safety data remain incomplete, especially for organic linkers and transformation products, and the candidate biomarkers discussed here lack validation for clinical selection in MOF-enabled cuproptosis therapy. We identify priorities in mitochondrial copper measurement, tumor heterogeneity, component disposition and manufacturing reproducibility. The evidence remains predominantly preclinical. The framework organizes further development around testable links between delivery, mechanism and tumor state; its predictive value and the clinical benefit of MOF-enabled cuproptosis remain to be established.
Abstract from PubMed Central (PMID 42992243, PMC13738817). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering
Cardiovascular therapeuticsDisease-Specific Determinants of Cardiovascular Nanomedicine: Mechanisms, Limitations, and Translational Opportunities
Molecular medicine reportsGraphene‑based nanomaterials for drug delivery: Design strategies, mechanisms and clinical perspectives (Review)
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
